Connor, Clark & Lunn Investment Management (CC&L)
CRNX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Sell
79,755
-20,812
-21% -$930K 0.01% 847
2025
Q4 		$4.68M Buy
100,567
+88,023
+702% +$3.92M 0.01% 664
2025
Q3 		$522K Buy
+12,544
New +$401K ﹤0.01% 1247
2025
Q1 		– Sell
-6,898
Closed -$353K – 1444
2024
Q4 		$353K Sell
6,898
-13,735
-67% -$768K ﹤0.01% 1226
2024
Q3 		$1.05M Buy
20,633
+505
+3% +$26K 0.01% 870
2024
Q2 		$902K Buy
+20,128
New +$930K ﹤0.01% 875

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return